Abbott to suspend marketing of obesity drug sibutramine in EU
This article was originally published in Scrip
Executive Summary
Abbott will suspend European sales of its anti-obesity drug Reductil (sibutramine) after the CHMP recommended its marketing suspension on the basis of the increased cardiovascular (CV) events seen with it in the SCOUT trial, which included patients at high risk for CV disease. Cardiovascular safety concerns have long plagued the drug.